GLP‑1 coverage crunch

Health plans across the U.S. are tightening coverage for GLP-1 obesity drugs, leaving millions of patients to switch medicines, appeal denials, or pay cash. (npr.org) GoodRx found that from 2025 to 2026, about 12 million people lost some coverage for Eli Lilly’s Zepbound and another 12 million lost some coverage for Novo Nordisk’s Wegovy. NPR reported that employers and insurers have been dropping benefits or adding tougher prior-authorization rules. (goodrx.com, npr.org) GLP-1 drugs mimic gut hormones that help regulate appetite and blood sugar, and the obesity versions are sold as Wegovy and Zepbound. They can cost hundreds of dollars a month without coverage, which is why benefit changes can quickly force patients to stop or switch treatment. (wegovy.com, zepbound.lilly.com) The coverage squeeze is colliding with a federal policy shift. The Centers for Medicare & Medicaid Services said on April 21 it is delaying the Medicare Part D portion of the BALANCE model for 2027 while it gathers more data, pausing one route that had been pitched to expand GLP-1 access. (aha.org) At the same time, Medicare is still moving ahead with a separate bridge program for weight-loss GLP-1 drugs. A Centers for Medicare & Medicaid Services spokesperson told USA Today that Medicare will offer the drugs through that program from July 1, 2026, through December 31, 2027. (usatoday.com) Patients shut out by insurance are being steered toward manufacturer cash-pay programs instead. Novo Nordisk says new Wegovy users can pay $199 a month for the first two lower-dose fills through June 30, 2026, before standard self-pay pricing rises to $349 a month for most pen doses, while Lilly advertises Zepbound self-pay pricing starting at $299 a month for a one-month KwikPen prescription for eligible commercially insured patients whose plans do not cover it. (novocare.com, zepbound.lilly.com) Retail and delivery companies are moving into that gap. Amazon said this week that it plans to sell the best-known GLP-1 weight-loss drugs and offer same-day delivery in the U.S., extending the push to make access hinge less on local pharmacy supply and more on direct fulfillment. (today.com) The backdrop has changed since last year’s shortage era. The Food and Drug Administration has said the injection shortages for semaglutide products including Wegovy and for tirzepatide products including Zepbound are resolved, narrowing the legal opening that had allowed many compounders to make copies. (fda.gov, fda.gov) Insurers say the drugs are expensive and coverage still varies sharply by employer, plan design, and diagnosis. Drugmakers and obesity specialists argue that stop-and-start coverage undermines long-term treatment for a chronic disease, and the next test will be whether Medicare’s July 1, 2026 bridge program eases pressure for patients who have run out of commercial options. (npr.org, usatoday.com)